Clinical Trials in San Diego

Showing 4661-4680 of 14,679 trials

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

NCT02023866

To evaluate safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) administered at a target maintenance dose of 1.3 g/m²/day in two divided doses, every 12 hours, for up to 6 months in patients with inherited mitochondrial disease.

Inherited Mitochondrial Disease, Including Leigh Syndrome

Amgen36 participantsStarted May 2014

San Diego, California, United States • Stanford, California, United States • Akron, Ohio, United States +2 more locations

COMPLETEDPhase 16.9 miles

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

NCT05794581

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Type 1 Diabetes

Carmot Therapeutics, Inc.32 participantsStarted Mar 2023

Chula Vista, California, United States

RECRUITINGPhase 111 miles

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

NCT06639724

This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).

Pancreatic Ductal Adenocarcinoma (PDAC)

University of California, San Diego36 participantsStarted Dec 2024

La Jolla, California, United States

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Find Trials by Condition in San Diego

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

The WEB-IT Clinical Study

PATHFINDER 2: a Multi-Cancer Early Detection Study

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

ANC-501 in the Treatment of Adults With Major Depressive Disorder

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors